| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/16/2008 | EP1911449A1 Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
| 04/16/2008 | EP1911446A2 The use of PPAR-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity |
| 04/16/2008 | EP1911445A2 Stable pharmaceutical formulation comprising an HMG-COA reductase inhibitor |
| 04/16/2008 | EP1911442A2 Preparation for the prevention and/or treatment of vascular disorders |
| 04/16/2008 | EP1910825A2 Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds |
| 04/16/2008 | EP1909837A2 Compositions for treatment of systemic mastocytosis |
| 04/16/2008 | EP1909835A1 Methods and compositions for treating female infertility using clomiphene |
| 04/16/2008 | EP1909801A2 Compostions containing pufa and/or uridine and methods of use thereof |
| 04/16/2008 | EP1909785A2 Use of progesterone receptor modulators |
| 04/16/2008 | EP1909781A1 Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance |
| 04/16/2008 | EP1909600A1 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 04/16/2008 | EP1633376B1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
| 04/16/2008 | EP1467771B1 Mycobacterial vaccine |
| 04/16/2008 | EP1423382B1 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/16/2008 | EP1250155B1 Angiogenesis and vascular permeability modulators and inhibitors |
| 04/16/2008 | EP1223952B1 Methods for treatment of solid tumors and metastasis by gene therapy |
| 04/16/2008 | CN101163505A Method of treatment using gh antagonist and somatostatin agonist |
| 04/16/2008 | CN101163504A 联合疗法 Combination therapy |
| 04/16/2008 | CN101163473A Anticancer combination therapy using sunitinib malate |
| 04/16/2008 | CN101163468A Novel combinational use of sulfonamide compound |
| 04/16/2008 | CN101161288A Enganced tumour cell cracking article of oligonucleotide and method for treating knub |
| 04/16/2008 | CN101161249A Method for extracting original mesenchyma and hematopoiesis trunks/ancestral cell from caesarean birth placenta for treating medulla scathe |
| 04/16/2008 | CN101161236A Method of producing drug-carrying nanometer particle of duplicate flocculation technics in microemulsion |
| 04/16/2008 | CN100381437C Compounds, compositions and methods |
| 04/16/2008 | CN100381174C Preparation method of medicine for treating male baldness and its clinical application |
| 04/16/2008 | CN100381169C Composite collagen eye drops |
| 04/16/2008 | CN100381119C Compositions for diabetes |
| 04/15/2008 | USRE40245 Gyrase inhibitors and uses thereof |
| 04/15/2008 | US7358386 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 04/15/2008 | US7358341 Secreted protein for use in diagnosis, prevention and treatment of thyroid gland disorders |
| 04/15/2008 | US7358333 Polypeptides of the IFNα-5 gene |
| 04/15/2008 | US7358329 Antagonists to chaperonin 10 |
| 04/15/2008 | US7358272 Reduction of levels of tumor necrosis factor-alpha and/or inhibition of phosphodiesterase 4; treating cancer, especially various types of leukemia |
| 04/15/2008 | US7358254 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 04/15/2008 | US7358245 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer |
| 04/15/2008 | US7358238 3-(2-Phenoxymethyl-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]azepin-9-one; inhibiting the activity of 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta HSD1); increase intracellular concentration of active glucocorticoid; metabolic disorders, insulin resistance, dyslipidemia, obesity |
| 04/15/2008 | US7358222 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs |
| 04/15/2008 | US7358086 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 04/15/2008 | US7358068 For use as therapeutic agents in viral infections by human and animal viruses and in cancers caused by oncogene viruses; non-sequence complementary mode of action; drug screening |
| 04/15/2008 | US7358066 Variants and exons of the GlyT1 transporter |
| 04/15/2008 | US7358058 Method and agents for the diagnosis and therapy of chronic inflammatory intestinal disease |
| 04/15/2008 | US7358056 Methods for modulating signal transduction mediated by TGF-β and related proteins |
| 04/15/2008 | US7358046 Sensitivity test to predict efficacy of anti-cancer therapies |
| 04/15/2008 | US7357938 Sulfacetamide formulations for treatment of rosacea |
| 04/15/2008 | US7357936 immunostimulant (3-de-O-acylated monophosphoryl lipid A) adsorbed onto metallic salt (aluminium hydroxide or aluminium phosphate); second salt with antigen which elicits immune response to polypeptide or pathogen; Hepatitis, human papilloma virus |
| 04/15/2008 | US7357934 Intracranial botulinum toxin therapy for focal epilepsy |
| 04/15/2008 | US7357930 Methods and formulations for targeting infectious agents bearing host cell proteins |
| 04/15/2008 | US7357924 Nucleic acids/proteins/antibodies/mimetics for cell differentiation/prolilferation control |
| 04/15/2008 | US7357810 High strength suture with absorbable core and suture anchor combination |
| 04/15/2008 | CA2411468C Thrombopoietin mimetics |
| 04/15/2008 | CA2381797C Composition comprising a tramadol material and an anticonvulsant drug |
| 04/15/2008 | CA2370201C Skin care compositions containing a combination of skin care actives |
| 04/13/2008 | CA2606658A1 Compositions and methods for treating neurological disorders or damage |
| 04/10/2008 | WO2008041767A1 Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
| 04/10/2008 | WO2008041751A1 Pharmaceutical preparation for treating fibromyalgia |
| 04/10/2008 | WO2008041665A1 Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis c |
| 04/10/2008 | WO2008041514A1 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 04/10/2008 | WO2008041236A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 04/10/2008 | WO2008041003A2 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith |
| 04/10/2008 | WO2008040967A1 Treatment of fibrosis |
| 04/10/2008 | WO2008040548A2 Treatment for non-alcoholic-steatohepatitis |
| 04/10/2008 | WO2008040361A2 Use of a combination of hypothermia inducing drugs |
| 04/10/2008 | WO2008020040A3 2,5-dihydroxybenzene compounds for the treatment of fibrosis |
| 04/10/2008 | WO2008020027A3 2,5-dihydroxybenzene compounds for the treatment of skin cancer |
| 04/10/2008 | WO2008010222A3 Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
| 04/10/2008 | WO2007118996A3 Use of at least one cytosolic phospholipase a2 inhibitor as a medicine for symptomatic treatment of mucoviscidosis |
| 04/10/2008 | WO2007115289A3 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 04/10/2008 | US20080086000 Prostaglandin reductase |
| 04/10/2008 | US20080085995 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/10/2008 | US20080085916 Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators |
| 04/10/2008 | US20080085902 Prevention or treatment of proliferative diseases by administering a VEGF inhibitor compound such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and one or more chemotherapeutic agents such as N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; cancer |
| 04/10/2008 | US20080085883 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| 04/10/2008 | US20080085872 Administering colesevelam hydrochloride, and an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: a cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin |
| 04/10/2008 | US20080085861 Gas1 polypeptides |
| 04/10/2008 | US20080085317 Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions |
| 04/10/2008 | US20080085292 Composite Scaffolds Seeded with Mammalian Cells |
| 04/10/2008 | US20080085269 Vaccine And Method For Treatment Of Neurodegenerative Diseases |
| 04/10/2008 | US20080085264 Targeting progenitor cells to bone marrow for prevention and treatment of cell proliferative disorders; regenerative medicine and tissue engineering |
| 04/10/2008 | CA2665435A1 Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats |
| 04/10/2008 | CA2665380A1 Treatment of insulin resistance and disorders associated therewith |
| 04/10/2008 | CA2665141A1 Composition comprising crustacean gastrolith components and its use |
| 04/10/2008 | CA2664356A1 Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor |
| 04/10/2008 | CA2664158A1 Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 04/09/2008 | EP1908481A1 Agent for reduction of bleeding in cerebrovascular disorder |
| 04/09/2008 | EP1908480A1 Interferon- alpha regulator |
| 04/09/2008 | EP1908467A1 Herpesvirus-derived therapeutic agent for pain |
| 04/09/2008 | EP1908463A2 Methods of inducing ovulation using a non-polypeptide camp level modulator |
| 04/09/2008 | EP1908462A2 Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| 04/09/2008 | EP1907006A2 Prevention and treatment of ophthalmic complications of diabetes |
| 04/09/2008 | EP1907005A1 Compositions for affecting weight loss |
| 04/09/2008 | EP1907004A2 Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer |
| 04/09/2008 | EP1907003A2 Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases |
| 04/09/2008 | EP1906966A2 Compositions for reducing the incidence of drug induced arrhythmia |
| 04/09/2008 | EP1906948A2 Treatment of cancer |
| 04/09/2008 | EP1906912A1 Method for prolonging the life of animals |
| 04/09/2008 | EP1906767A1 Lycopene formulations for the treatment of atherosclerotic conditions |
| 04/09/2008 | EP1670526B1 Apparatus and method for administering a therapeutic agent |
| 04/09/2008 | EP1572133B1 Method for identifying modulators of human orexin-2 receptor |
| 04/09/2008 | EP1474171B1 Weight management system for obese animals |
| 04/09/2008 | EP1360311B1 Membrane penetrating peptides and uses thereof |